1H-MRS metabolite concentrations at baseline and at follow-up after one year of natalizumab treatment (presented as units of mM aq).

To the left the mean and standard deviation (SD) of metabolite concentrations among healthy controls (HC).pa refers to significance level with independent samples t-test comparing HC with MS patients at baseline. Significant differences were still valid when adjusting for age using logistic regression analyses. To the right the mean and the standard deviation (SD) of metabolite concentrations among MS patients are presented at baseline and at follow-up. At the far right the mean difference in metabolite concentrations post-to pretreatment are presented with a 95% confidence interval (CI).pb refers to significance level with paired samples t-test comparing levels of metabolites in MS patients post-to pretreatment.Abbreviations: tCr = total creatine; tNA = total N-acetylaspartate; mIns = myo-inositol; tCho = total choline; tGlx = glutamate + glutamine; Lac = lactate.

左侧展示健康对照组（healthy controls, HC）的代谢物浓度均值与标准差（standard deviation, SD）。pa指代采用独立样本t检验，比较基线状态下健康对照组与多发性硬化症（multiple sclerosis, MS）患者的显著性水平；经logistic回归分析校正年龄后，上述显著性差异依然成立。右侧展示了多发性硬化症患者在基线与随访阶段的代谢物浓度均值及标准差。最右侧则呈现了代谢物浓度在治疗后与治疗前的均值差值，并附带95%置信区间（confidence interval, CI）。pb指代采用配对样本t检验，比较多发性硬化症患者治疗前后的代谢物水平的显著性水平。缩写说明：tCr为总肌酸（total creatine）；tNA为总N-乙酰天门冬氨酸（total N-acetylaspartate）；mIns为肌醇（myo-inositol）；tCho为总胆碱（total choline）；tGlx为谷氨酸与谷氨酰胺之和（glutamate + glutamine）；Lac为乳酸（lactate）。